Literature DB >> 33561076

Potentially Modifiable Factors Associated with Adherence to Adjuvant Endocrine Therapy among Breast Cancer Survivors: A Systematic Review.

Kirsti I Toivonen1, Tamara M Williamson1, Linda E Carlson2,3, Lauren M Walker2,3, Tavis S Campbell1.   

Abstract

Adjuvant endocrine therapy (AET) reduces risk of breast cancer recurrence. However, suboptimal adherence and persistence to AET remain important clinical issues. Understanding factors associated with adherence may help inform efforts to improve use of AET as prescribed. The present systematic review examined potentially modifiable factors associated with adherence to AET in accordance with PRISMA guidelines (PROSPERO registration ID: CRD42019124200). All studies were included, whether factors were significantly associated with adherence or results were null. This review also accounted for the frequency with which a potentially modifiable factor was examined and whether univariate or multivariate models were used. This review also examined whether methodological or sample characteristics were associated with the likelihood of a factor being associated with AET adherence. A total of 68 articles were included. Potentially modifiable factors were grouped into six categories: side effects, attitudes toward AET, psychological factors, healthcare provider-related factors, sociocultural factors, and general/quality of life factors. Side effects were less likely to be associated with adherence in studies with retrospective or cross-sectional than prospective designs. Self-efficacy (psychological factor) and positive decisional balance (attitude toward AET) were the only potentially modifiable factors examined ≥10 times and associated with adherence or persistence ≥75% of the time in both univariate and multivariate models. Self-efficacy and decisional balance (i.e., weight of pros vs. cons) were the potentially modifiable factors most consistently associated with adherence, and hence may be worth focusing on as targets for interventions to improve AET adherence among breast cancer survivors.

Entities:  

Keywords:  adherence; adjuvant endocrine therapy; breast cancer; review

Year:  2020        PMID: 33561076     DOI: 10.3390/cancers13010107

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  7 in total

1.  A telehealth intervention for symptom management, distress, and adherence to adjuvant endocrine therapy: A randomized controlled trial.

Authors:  Jamie M Jacobs; Kathryn Post; Katina Massad; Nora K Horick; Emily A Walsh; Julia Cohn; Chelsea S Rapoport; Amy J Clara; Michael H Antoni; Steven A Safren; Ann H Partridge; Jeffrey M Peppercorn; Elyse R Park; Jennifer S Temel; Joseph A Greer
Journal:  Cancer       Date:  2022-08-04       Impact factor: 6.921

2.  Randomized Controlled Pilot Trial of a Low-Touch Remotely-Delivered Values Intervention to Promote Adherence to Adjuvant Endocrine Therapy Among Breast Cancer Survivors.

Authors:  Joanna J Arch; Catherine M Crespi; Michael E Levin; Sarah R Genung; Madeline Nealis; Jill L Mitchell; Emma E Bright; Karen Albright; Jessica F Magidson; Annette L Stanton
Journal:  Ann Behav Med       Date:  2022-08-02

3.  A Survey of Potentially Modifiable Patient-Level Factors Associated with Self-Report and Objectively Measured Adherence to Adjuvant Endocrine Therapies After Breast Cancer.

Authors:  Kirsti I Toivonen; Linda E Carlson; Joshua A Rash; Tavis S Campbell
Journal:  Patient Prefer Adherence       Date:  2021-09-15       Impact factor: 2.711

4.  Acupuncture versus cognitive behavioral therapy for pain among cancer survivors with insomnia: an exploratory analysis of a randomized clinical trial.

Authors:  Mingxiao Yang; Kevin T Liou; Sheila N Garland; Ting Bao; Tony K W Hung; Susan Q Li; Yuelin Li; Jun J Mao
Journal:  NPJ Breast Cancer       Date:  2021-11-30

5.  Supporting adjuvant endocrine therapy adherence in women with breast cancer: the development of a complex behavioural intervention using Intervention Mapping guided by the Multiphase Optimisation Strategy.

Authors:  Sophie M C Green; David P French; Christopher D Graham; Louise H Hall; Nikki Rousseau; Robbie Foy; Jane Clark; Catherine Parbutt; Erin Raine; Benjamin Gardner; Galina Velikova; Sally J L Moore; Jacqueline Buxton; Samuel G Smith
Journal:  BMC Health Serv Res       Date:  2022-08-24       Impact factor: 2.908

6.  Racial Differences in Patient-Reported Symptoms and Adherence to Adjuvant Endocrine Therapy Among Women With Early-Stage, Hormone Receptor-Positive Breast Cancer.

Authors:  Xin Hu; Mark S Walker; Edward Stepanski; Cameron M Kaplan; Michelle Y Martin; Gregory A Vidal; Lee S Schwartzberg; Ilana Graetz
Journal:  JAMA Netw Open       Date:  2022-08-01

7.  Person-centred support programme (RESPECT intervention) for women with breast cancer treated with endocrine therapy: a feasibility study.

Authors:  Susanne Ahlstedt Karlsson; Ingela Henoch; Roger Olofsson Bagge; Catarina Wallengren
Journal:  BMJ Open       Date:  2022-10-05       Impact factor: 3.006

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.